Venus Medtech (Hangzhou) (HKSE:02500) EPS (Basic): HK$-1.02 (TTM As of Dec. 2025)


HKSE:02500 Venus Medtech (Hangzhou) Inc HKSE:02500
52 GF Score
Price HK$1.35
GF Value HK$3.39
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Venus Medtech (Hangzhou) EPS (Basic)?

Venus Medtech (Hangzhou) HKSE:02500 +12.50% 52 EPS (Basic) is HK$-1.02 as of Dec. 2025. GuruFocus rates HKSE:02500 with a GF Score™ of 52/100 and a GF Value™ of HK$3.39 (Possible Value Trap). The stock has 4 warning signs investors should review.

Venus Medtech (Hangzhou)'s basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was HK$-0.69. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-1.02.

Venus Medtech (Hangzhou)'s EPS (Diluted) for the six months ended in Dec. 2025 was HK$-0.69. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-1.02.

Venus Medtech (Hangzhou)'s EPS without NRI for the six months ended in Dec. 2025 was HK$-0.71. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -1.06.

During the past 3 years, the average EPS without NRI Growth Rate was 26.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Venus Medtech (Hangzhou)'s highest 3-Year average EPS without NRI Growth Rate was 26.30% per year. The lowest was -47.80% per year. And the median was -19.25% per year.

Venus Medtech (Hangzhou)  (HKSE:02500) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Venus Medtech (Hangzhou) EPS (Basic) Related Terms

Venus Medtech (Hangzhou) EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Venus Medtech (Hangzhou)'s EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Venus Medtech (Hangzhou) EPS (Basic) Chart

Venus Medtech (Hangzhou) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only -1.04 -2.70 -1.76 -1.74 -1.03

Venus Medtech (Hangzhou) Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.89 -0.51 -1.24 -0.34 -0.69
HKSE:02500
52GF Score
Venus Medtech (Hangzhou) Inc HKSE:02500
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Venus Medtech (Hangzhou) EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Venus Medtech (Hangzhou)'s Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-450.389-0)/437.897
=-1.03

Venus Medtech (Hangzhou)'s Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-301.503-0)/437.897
=-0.69

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of HK$-1.02 mean?
Venus Medtech (Hangzhou) (HKSE:02500) has a EPS (Basic) of HK$-1.02 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Venus Medtech (Hangzhou) and its competitors.
Is Venus Medtech (Hangzhou)'s EPS (Basic) too high?
Venus Medtech (Hangzhou)'s current EPS (Basic) is HK$-1.02. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s EPS (Basic) compare to ABT and SYK?
Venus Medtech (Hangzhou)'s EPS (Basic) of HK$-1.02 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Venus Medtech (Hangzhou) and its competitors. Venus Medtech (Hangzhou)'s current EPS (Basic) is HK$-1.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) (HKSE:02500) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.39, compared to a current price of HK$1.35 — trading 60.2% below its estimated fair value. The current EPS (Basic) is HK$-1.02. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (HKSE:02500), the current EPS (Basic) is HK$-1.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Venus Medtech (Hangzhou) (HKSE:02500) Overvalued in 2026?

Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued. The current stock price of HK$1.35 is trading 60.2% below its estimated GF Value™ of HK$3.39. GuruFocus considers Venus Medtech (Hangzhou) to be Possible Value Trap.

Key valuation signals for HKSE:02500:

  • EPS (Basic): HK$-1.02
  • GF Value™: HK$3.39 vs. price of HK$1.35 (60.2% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Venus Medtech (Hangzhou) Business Description

Address No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score

Get the complete analysis for HKSE:02500

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.35
Price
HK$3.39
GF Value